Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) today and set a ...

Rebranding efforts include a new logo, overall brand presence, and corporate design.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to market to treat the liver disease non-alcoholic ...

Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $377.46. Madrigal Pharmaceuticals ( NASDAQ:MDGL – Get Free Report ) last posted its earnings results on Wednesday ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

PORT ST. LUCIE, Fla. -- New York Mets infielder Nick Madrigal could miss the entire 2025 season with a fractured left shoulder. Manager Carlos Mendoza told reporters Friday that Madrigal needs ...